- Home
- VCYT
VCYT
Veracyte Inc.
as 05-30-2025 10:44am EST
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $39.89 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.73 - $47.32 | Next Earning Date: | 05-07-2025 |
| Revenue: | $463,393,000 | Revenue Growth: | 23.42% |
| Revenue Growth (this year): | 12.43% | Revenue Growth (next year): | 10.05% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leite John | VCYT | Chief Commercial Officer-CLIA | Mar 6 '25 | Sell | $31.50 | 7,411 | $234,629.55 | 100,249 | |
| Stapley Marc | VCYT | Chief Executive Officer | Mar 4 '25 | Sell | $33.70 | 52,697 | $1,756,855.23 | 292,543 | |
| McGuire Annie | VCYT | SVP, General Counsel | Mar 4 '25 | Sell | $33.69 | 1,142 | $38,476.49 | 70,308 | |
| Febbo Phillip G. | VCYT | Chief Scientific & Med Officer | Mar 4 '25 | Sell | $33.41 | 8,037 | $268,012.94 | 86,110 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO
Business Wire
2 days ago
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
Business Wire
10 days ago
Veracyte to Participate in Upcoming Investor Conferences
Zacks
11 days ago
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Simply Wall St.
20 days ago
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next
Zacks
21 days ago
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
Simply Wall St.
21 days ago
Veracyte First Quarter 2025 Earnings: Beats Expectations
Zacks
22 days ago
What Makes Veracyte (VCYT) a New Buy Stock
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.